Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

QSM for detection of hemorrhaging cysts and risk stratification in ADPKD

Clinical Trial Details

This study aims to learn ways to improve the way MRI scans are done to make them more accurate and easier for patients, particularly by using a method that allows them to breathe normally during the scan. 

We also hope to learn ways to improve our understanding of kidney disease. This could lead to better diagnostic tools, more effective treatments, and a deeper insight into kidney function and failure, ultimately benefiting future patients. 

Participants will be asked to undergo up to two MRI scans without contrast. The MRI scanner will take cross-section pictures of the abdomen using magnetic fields, radio waves, and copper wires. After a break, participants will be asked to walk (<10 min) to a different imaging facility at Weill Cornell Medicine to undergo an identical imaging procedure.

Key Eligibility: 

 Inclusion Criteria:

  1. Healthy participant or Autodominant Polycystic Kidney Disease (ADPKD) patients
  2. Men and women aged 18 years or older
  3. No known hematological and liver disease, and no contraindications for MRI (e.g. cardiac pacemaker, implantable cardiac defibrillator, aneurysm clip, cochlear implants, shrapnel, history of metallic fragments, or neurostimulators).
  4. No known renal carcinoma and ESRD. For ADPKD patients, scheduled to undergo standard-of-care nephrectomy

Exclusion Criteria

  1. Pregnant or breastfeeding
  2. Have a history of claustrophobia
  3. Questionable medical history of metallic fragments
  4. Unstable angina or New York Heart Association class IV heart failure

Study contact by location

Upper East Side - Manhattan

Contact(s)

Jincy Koshy
646-962-2964

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

2408027907

Status

Not Yet Recruiting

Age Group

Adult

Sponsor